                         SEQUENCE LISTING

<110>  AMLO Biosciences Limited
 
<120>  Monoclonal antibodies against Ambra-1

<130>  P031381WO

<150>  GB1818618.9
<151>  2018-11-15

<150>  GB1911211.9
<151>  2019-08-06

<160>  61    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR1 of the anti-Ambra-1 antibody

<400>  1

Ser Tyr Trp Ile His 
1               5   


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR2 of the anti-Ambra-1 antibody

<400>  2

Thr Ile Phe Pro Ser Arg Ser Tyr Thr Thr Tyr Ser Pro Ser Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  3
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR3 of the anti-Ambra-1 antibody

<400>  3

Asp Thr Pro Ser Thr Ala Leu Lys Ser Pro Phe Asp Tyr 
1               5                   10              


<210>  4
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR1 of the anti-Ambra-1 antibody

<400>  4

Ser Gly Ser Ser Ser Asn Ile Gly Tyr Asn Tyr Val Tyr 
1               5                   10              


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR2 of the anti-Ambra-1 antibody

<400>  5

Glu Asn Asn Lys Arg Pro Ser 
1               5           


<210>  6
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR3 of the anti-Ambra-1 antibody

<400>  6

Ser Ser Trp Asp Ser His Ser Asn Ser Tyr Val 
1               5                   10      


<210>  7
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCFR1 of the anti-Ambra-1 antibody

<400>  7

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser 
            20                  25                  30  


<210>  8
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCFR2 of the anti-Ambra-1 antibody

<400>  8

Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly 
1               5                   10                  


<210>  9
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCFR3 of the anti-Ambra-1 antibody

<400>  9

Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln 
1               5                   10                  15      


Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  10
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCFR4 of the anti-Ambra-1 antibody

<400>  10

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  11
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCFR1 of the anti-Ambra-1 antibody

<400>  11

Asp Ile Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys 
            20          


<210>  12
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCFR2 of the anti-Ambra-1 antibody

<400>  12

Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  13
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCFR3 of the anti-Ambra-1 antibody

<400>  13

Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser 
1               5                   10                  15      


Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys 
            20                  25                  30          


<210>  14
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCFR4 of the anti-Ambra-1 antibody

<400>  14

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 
1               5                   10          


<210>  15
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH domain of the anti-Ambra-1 antibody

<400>  15

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Ser Tyr 
            20                  25                  30          


Trp Ile His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Phe Pro Ser Arg Ser Tyr Thr Thr Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Thr Pro Ser Thr Ala Leu Lys Ser Pro Phe Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  16
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL domain of the anti-Ambra-1 antibody

<400>  16

Asp Ile Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Tyr Asn 
            20                  25                  30          


Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Glu Asn Asn Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln 
65                  70                  75                  80  


Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Ser His Ser 
                85                  90                  95      


Asn Ser Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 
            100                 105                 110         


<210>  17
<211>  224
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fd chain (VH domain and constant domain) of the Fab region of the
       anti-Ambra-1 antibody

<400>  17

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Ser Tyr 
            20                  25                  30          


Trp Ile His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Thr Ile Phe Pro Ser Arg Ser Tyr Thr Thr Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Thr Pro Ser Thr Ala Leu Lys Ser Pro Phe Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 
        115                 120                 125             


Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 
    130                 135                 140                 


Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 
145                 150                 155                 160 


Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 
                165                 170                 175     


Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 
            180                 185                 190         


Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 
        195                 200                 205             


His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 
    210                 215                 220                 


<210>  18
<211>  215
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain (VL domain and constant domain) of the Fab region of 
       the anti-Ambra-1 antibody

<400>  18

Asp Ile Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Tyr Asn 
            20                  25                  30          


Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Glu Asn Asn Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln 
65                  70                  75                  80  


Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Ser His Ser 
                85                  90                  95      


Asn Ser Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 
            100                 105                 110         


Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 
        115                 120                 125             


Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 
    130                 135                 140                 


Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 
145                 150                 155                 160 


Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 
                165                 170                 175     


Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 
            180                 185                 190         


Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 
        195                 200                 205             


Thr Val Ala Pro Thr Glu Ala 
    210                 215 


<210>  19
<211>  2085
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Fd chain of the Fab region and tags of the anti-Ambra-1 antibody

<400>  19
gaagtgcaat tggtgcagag cggtgcggaa gtgaaaaaac cgggcgaaag cctgaaaatt       60

agctgcaaag gctccggata tagcttctct tcttactgga tccattgggt gcgccagatg      120

ccgggcaaag gtctcgagtg gatgggcact atcttcccgt ctcgtagcta caccacttat      180

agcccgagct ttcagggcca ggtgaccatt agcgcggata aaagcatcag caccgcgtat      240

ctgcaatgga gcagcctgaa agcgagcgat accgcgatgt attattgcgc gcgtgacact      300

ccgtctactg ctctgaaatc tccgttcgat tactggggcc aaggcaccct ggtgactgtt      360

agctcagcgt cgaccaaagg cccgagcgtg tttccgctgg ccccgagcag caaaagcacc      420

agcggcggca ccgccgcact gggctgcctg gtgaaagatt atttcccgga accagtgacc      480

gtgagctgga acagcggtgc cctgaccagc ggcgtgcata cctttccggc ggtgctgcaa      540

agcagcggcc tgtatagcct gagcagcgtt gtgaccgtgc cgagcagcag cctgggcacc      600

cagacctata tttgcaacgt caaccataaa ccgagcaaca ccaaagtcga taaaaaagtc      660

gaaccgaaaa gcgaattcaa ggctgaaatg cctgttctgg aaaaccgggc tgctcagggc      720

gatattacta cacccggcgg tgctcgccgt ttaacgggtg atcagactgc cgctctgcgt      780

gattctctta gcgataaacc tgcaaaaaat attattttgc tgattggcga tgggatgggg      840

gactcggaaa ttactgccgc acgtaattat gccgaaggtg cgggcggctt ttttaaaggt      900

atagatgcct taccgcttac cgggcaatac actcactatg cgctgaatag aaaaaccggc      960

aaaccggact acgtcaccag ctcggctgca tcagcaaccg cctggtcaac cggtgtcaaa     1020

acctataacg gcgcgctggg cgtcgatatt cacgaaaaag atcacccaac gattctggaa     1080

atggcaaaag ccgcaggtct ggcgaccggt aacgtttcta ccgcagagtt gcaggatgcc     1140

acgcccgctg cgctggtggc acatgtgacc tcgcgcaaat gctacggtcc gagcgcgacc     1200

agtgaaaaat gtccgggtaa cgctctggaa aaaggcggaa aaggatcgat taccgaacag     1260

ctgcttaacg ctcgtgccga cgttacgctt ggcggcggcg caaaaacctt tgctgaaacg     1320

gcaaccgctg gtgaatggca gggaaaaacg ctgcgtgaac aggcacaggc gcgtggttat     1380

cagttggtga gcgatgctgc ctcactgaac tcggtgacgg aagcgaatca gcaaaaaccc     1440

ctgcttggcc tgtttgctga cggcaatatg ccagtgcgct ggctaggacc gaaagcaacg     1500

taccatggca atatcgataa gcccgcagtc acctgtacgc caaatccgca acgtaatgac     1560

agtgtaccaa ccctggcgca gatgaccgac aaagccattg aattgttgag taaaaatgag     1620

aaaggctttt tcctgcaagt tgaaggtgcg tcaatcgata aacaggatca tgctgcgaat     1680

ccttgtgggc aaattggcga gacggtcgat ctcgatgaag ccgtacaacg ggcgctggag     1740

ttcgctaaaa aggagggtaa cacgctggtc atagtcaccg ctgatcacgc ccacgccagc     1800

cagattgttg cgccggatac caaagctccg ggcctcaccc aggcgctaaa taccaaagat     1860

ggcgcagtga tggtgatgag ttacgggaac tccgaagagg attcacaaga acataccggc     1920

agtcagttgc gtattgcggc gtatggcccg catgccgcca atgttgttgg actgaccgac     1980

cagaccgatc tcttctacac catgaaagcc gctctggggc tgaaaggcgc gccggactat     2040

aaagatgacg atgacaaagg cgcgccgcac catcatcacc atcac                     2085


<210>  20
<211>  645
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  light chain of the Fab region of the anti-Ambra-1 antibody

<400>  20
gatatcgtgc tgacccagcc gccgagcgtg agcggtgcac cgggccagcg cgtgaccatt       60

agctgtagcg gcagcagcag caacattggt tacaactacg tgtactggta ccagcagctg      120

ccgggcacgg cgccgaaact gctgatctac gaaaacaaca aacgcccgag cggcgtgccg      180

gatcgcttta gcggatccaa aagcggcacc agcgccagcc tggcgattac cggcctgcaa      240

gcagaagacg aagcggatta ttactgctct tcttgggact ctcattctaa ctcttacgtg      300

tttggcggcg gcacgaagtt aaccgttctt ggccagccga aagccgcccc aagcgtgacc      360

ctgtttccgc cgagcagcga agaactgcaa gccaacaaag ccaccctggt ttgcctgatc      420

agcgattttt atccgggtgc cgtgaccgtg gcctggaaag ccgatagcag cccggtgaaa      480

gccggcgtgg aaaccaccac cccgagcaaa cagagcaaca acaaatatgc cgccagcagc      540

tatctgagcc tgaccccgga acagtggaaa agccatcgca gctatagttg tcaagtgacc      600

catgaaggca gcaccgtgga aaaaaccgtg gccccgaccg aggcc                      645


<210>  21
<211>  1298
<212>  PRT
<213>  Homo sapiens

<400>  21

Met Lys Val Val Pro Glu Lys Asn Ala Val Arg Ile Leu Trp Gly Arg 
1               5                   10                  15      


Glu Arg Gly Ala Arg Ala Met Gly Ala Gln Arg Leu Leu Gln Glu Leu 
            20                  25                  30          


Val Glu Asp Lys Thr Arg Trp Met Lys Trp Glu Gly Lys Arg Val Glu 
        35                  40                  45              


Leu Pro Asp Ser Pro Arg Ser Thr Phe Leu Leu Ala Phe Ser Pro Asp 
    50                  55                  60                  


Arg Thr Leu Leu Ala Ser Thr His Val Asn His Asn Ile Tyr Ile Thr 
65                  70                  75                  80  


Glu Val Lys Thr Gly Lys Cys Val His Ser Leu Ile Gly His Arg Arg 
                85                  90                  95      


Thr Pro Trp Cys Val Thr Phe His Pro Thr Ile Ser Gly Leu Ile Ala 
            100                 105                 110         


Ser Gly Cys Leu Asp Gly Glu Val Arg Ile Trp Asp Leu His Gly Gly 
        115                 120                 125             


Ser Glu Ser Trp Phe Thr Asp Ser Asn Asn Ala Ile Ala Ser Leu Ala 
    130                 135                 140                 


Phe His Pro Thr Ala Gln Leu Leu Leu Ile Ala Thr Ala Asn Glu Ile 
145                 150                 155                 160 


His Phe Trp Asp Trp Ser Arg Arg Glu Pro Phe Ala Val Val Lys Thr 
                165                 170                 175     


Ala Ser Glu Met Glu Arg Val Arg Leu Val Arg Phe Asp Pro Leu Gly 
            180                 185                 190         


His Tyr Leu Leu Thr Ala Ile Val Asn Pro Ser Asn Gln Gln Gly Asp 
        195                 200                 205             


Asp Glu Pro Glu Ile Pro Ile Asp Gly Thr Glu Leu Ser His Tyr Arg 
    210                 215                 220                 


Gln Arg Ala Leu Leu Gln Ser Gln Pro Val Arg Arg Thr Pro Leu Leu 
225                 230                 235                 240 


His Asn Phe Leu His Met Leu Ser Ser Arg Ser Ser Gly Ile Gln Val 
                245                 250                 255     


Gly Glu Gln Ser Thr Val Gln Asp Ser Ala Thr Pro Ser Pro Pro Pro 
            260                 265                 270         


Pro Pro Pro Gln Pro Ser Thr Glu Arg Pro Arg Thr Ser Ala Tyr Ile 
        275                 280                 285             


Arg Leu Arg Gln Arg Val Ser Tyr Pro Thr Ala Glu Cys Cys Gln His 
    290                 295                 300                 


Leu Gly Ile Leu Cys Leu Cys Ser Arg Cys Ser Gly Thr Arg Val Pro 
305                 310                 315                 320 


Ser Leu Leu Pro His Gln Asp Ser Val Pro Pro Ala Ser Ala Arg Ala 
                325                 330                 335     


Thr Thr Pro Ser Phe Ser Phe Val Gln Thr Glu Pro Phe His Pro Pro 
            340                 345                 350         


Glu Gln Ala Ser Ser Thr Gln Gln Asp Gln Gly Leu Leu Asn Arg Pro 
        355                 360                 365             


Ser Ala Phe Ser Thr Val Gln Ser Ser Thr Ala Gly Asn Thr Leu Arg 
    370                 375                 380                 


Asn Leu Ser Leu Gly Pro Thr Arg Arg Ser Leu Gly Gly Pro Leu Ser 
385                 390                 395                 400 


Ser His Pro Ser Arg Tyr His Arg Glu Ile Ala Pro Gly Leu Thr Gly 
                405                 410                 415     


Ser Glu Trp Thr Arg Thr Val Leu Ser Leu Asn Ser Arg Ser Glu Ala 
            420                 425                 430         


Glu Ser Met Pro Pro Pro Arg Thr Ser Ala Ser Ser Val Ser Leu Leu 
        435                 440                 445             


Ser Val Leu Arg Gln Gln Glu Gly Gly Ser Gln Ala Ser Val Tyr Thr 
    450                 455                 460                 


Ser Ala Thr Glu Gly Arg Gly Phe Pro Ala Ser Gly Leu Ala Thr Glu 
465                 470                 475                 480 


Ser Asp Gly Gly Asn Gly Ser Ser Gln Asn Asn Ser Gly Ser Ile Arg 
                485                 490                 495     


His Glu Leu Gln Cys Asp Leu Arg Arg Phe Phe Leu Glu Tyr Asp Arg 
            500                 505                 510         


Leu Gln Glu Leu Asp Gln Ser Leu Ser Gly Glu Ala Pro Gln Thr Gln 
        515                 520                 525             


Gln Ala Gln Glu Met Leu Asn Asn Asn Ile Glu Ser Glu Arg Pro Gly 
    530                 535                 540                 


Pro Ser His Gln Pro Thr Pro His Ser Ser Glu Asn Asn Ser Asn Leu 
545                 550                 555                 560 


Ser Arg Gly His Leu Asn Arg Cys Arg Ala Cys His Asn Leu Leu Thr 
                565                 570                 575     


Phe Asn Asn Asp Thr Leu Arg Trp Glu Arg Thr Thr Pro Asn Tyr Ser 
            580                 585                 590         


Ser Gly Glu Ala Ser Ser Ser Trp Gln Val Pro Ser Ser Phe Glu Ser 
        595                 600                 605             


Val Pro Ser Ser Gly Ser Gln Leu Pro Pro Leu Glu Arg Thr Glu Gly 
    610                 615                 620                 


Gln Thr Pro Ser Ser Ser Arg Leu Glu Leu Ser Ser Ser Ala Ser Pro 
625                 630                 635                 640 


Gln Glu Glu Arg Thr Val Gly Val Ala Phe Asn Gln Glu Thr Gly His 
                645                 650                 655     


Trp Glu Arg Ile Tyr Thr Gln Ser Ser Arg Ser Gly Thr Val Ser Gln 
            660                 665                 670         


Glu Ala Leu His Gln Asp Met Pro Glu Glu Ser Ser Glu Glu Asp Ser 
        675                 680                 685             


Leu Arg Arg Arg Leu Leu Glu Ser Ser Leu Ile Ser Leu Ser Arg Tyr 
    690                 695                 700                 


Asp Gly Ala Gly Ser Arg Glu His Pro Ile Tyr Pro Asp Pro Ala Arg 
705                 710                 715                 720 


Leu Ser Pro Ala Ala Tyr Tyr Ala Gln Arg Met Ile Gln Tyr Leu Ser 
                725                 730                 735     


Arg Arg Asp Ser Ile Arg Gln Arg Ser Met Arg Tyr Gln Gln Asn Arg 
            740                 745                 750         


Leu Arg Ser Ser Thr Ser Ser Ser Ser Ser Asp Asn Gln Gly Pro Ser 
        755                 760                 765             


Val Glu Gly Thr Asp Leu Glu Phe Glu Asp Phe Glu Asp Asn Gly Asp 
    770                 775                 780                 


Arg Ser Arg His Arg Ala Pro Arg Asn Ala Arg Met Ser Ala Pro Ser 
785                 790                 795                 800 


Leu Gly Arg Phe Val Pro Arg Arg Phe Leu Leu Pro Glu Tyr Leu Pro 
                805                 810                 815     


Tyr Ala Gly Ile Phe His Glu Arg Gly Gln Pro Gly Leu Ala Thr His 
            820                 825                 830         


Ser Ser Val Asn Arg Val Leu Ala Gly Ala Val Ile Gly Asp Gly Gln 
        835                 840                 845             


Ser Ala Val Ala Ser Asn Ile Ala Asn Thr Thr Tyr Arg Leu Gln Trp 
    850                 855                 860                 


Trp Asp Phe Thr Lys Phe Asp Leu Pro Glu Ile Ser Asn Ala Ser Val 
865                 870                 875                 880 


Asn Val Leu Val Gln Asn Cys Lys Ile Tyr Asn Asp Ala Ser Cys Asp 
                885                 890                 895     


Ile Ser Ala Asp Gly Gln Leu Leu Ala Ala Phe Ile Pro Ser Ser Gln 
            900                 905                 910         


Arg Gly Phe Pro Asp Glu Gly Ile Leu Ala Val Tyr Ser Leu Ala Pro 
        915                 920                 925             


His Asn Leu Gly Glu Met Leu Tyr Thr Lys Arg Phe Gly Pro Asn Ala 
    930                 935                 940                 


Ile Ser Val Ser Leu Ser Pro Met Gly Arg Tyr Val Met Val Gly Leu 
945                 950                 955                 960 


Ala Ser Arg Arg Ile Leu Leu His Pro Ser Thr Glu His Met Val Ala 
                965                 970                 975     


Gln Val Phe Arg Leu Gln Gln Ala His Gly Gly Glu Thr Ser Met Arg 
            980                 985                 990         


Arg Val Phe Asn Val Leu Tyr Pro  Met Pro Ala Asp Gln  Arg Arg His 
        995                 1000                 1005             


Val Ser  Ile Asn Ser Ala Arg  Trp Leu Pro Glu Pro  Gly Leu Gly 
    1010                 1015                 1020             


Leu Ala  Tyr Gly Thr Asn Lys  Gly Asp Leu Val Ile  Cys Arg Pro 
    1025                 1030                 1035             


Glu Ala  Leu Asn Ser Gly Val  Glu Tyr Tyr Trp Asp  Gln Leu Asn 
    1040                 1045                 1050             


Glu Thr  Val Phe Thr Val His  Ser Asn Ser Arg Ser  Ser Glu Arg 
    1055                 1060                 1065             


Pro Gly  Thr Ser Arg Ala Thr  Trp Arg Thr Asp Arg  Asp Met Gly 
    1070                 1075                 1080             


Leu Met  Asn Ala Ile Gly Leu  Gln Pro Arg Asn Pro  Ala Thr Ser 
    1085                 1090                 1095             


Val Thr  Ser Gln Gly Thr Gln  Thr Leu Ala Leu Gln  Leu Gln Asn 
    1100                 1105                 1110             


Ala Glu  Thr Gln Thr Glu Arg  Glu Val Pro Glu Pro  Gly Thr Ala 
    1115                 1120                 1125             


Ala Ser  Gly Pro Gly Glu Gly  Glu Gly Ser Glu Tyr  Gly Ala Ser 
    1130                 1135                 1140             


Gly Glu  Asp Ala Leu Ser Arg  Ile Gln Arg Leu Met  Ala Glu Gly 
    1145                 1150                 1155             


Gly Met  Thr Ala Val Val Gln  Arg Glu Gln Ser Thr  Thr Met Ala 
    1160                 1165                 1170             


Ser Met  Gly Gly Phe Gly Asn  Asn Ile Ile Val Ser  His Arg Ile 
    1175                 1180                 1185             


His Arg  Ser Ser Gln Thr Gly  Thr Glu Pro Gly Ala  Ala His Thr 
    1190                 1195                 1200             


Ser Ser  Pro Gln Pro Ser Thr  Ser Arg Gly Leu Leu  Pro Glu Ala 
    1205                 1210                 1215             


Gly Gln  Leu Ala Glu Arg Gly  Leu Ser Pro Arg Thr  Ala Ser Trp 
    1220                 1225                 1230             


Asp Gln  Pro Gly Thr Pro Gly  Arg Glu Pro Thr Gln  Pro Thr Leu 
    1235                 1240                 1245             


Pro Ser  Ser Ser Pro Val Pro  Ile Pro Val Ser Leu  Pro Ser Ala 
    1250                 1255                 1260             


Glu Gly  Pro Thr Leu His Cys  Glu Leu Thr Asn Asn  Asn His Leu 
    1265                 1270                 1275             


Leu Asp  Gly Gly Ser Ser Arg  Gly Asp Ala Ala Gly  Pro Arg Gly 
    1280                 1285                 1290             


Glu Pro  Arg Asn Arg 
    1295             


<210>  22
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR1 of the anti-Loricrin antibody

<400>  22

Asp Tyr Tyr Ile His 
1               5   


<210>  23
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR2 of the anti-Loricrin antibody

<400>  23

Val Ile Ser Pro Asn Ser Gly Lys Thr Asn Tyr Ala Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  24
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR3 of the anti-Loricrin antibody

<400>  24

Asp Leu Tyr Pro Asp Ser Ser Ala Phe Asp Ile 
1               5                   10      


<210>  25
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR1 of the anti-Loricrin antibody

<400>  25

Ser Gly Asp Asn Leu Gly Asp Lys Tyr Ala His 
1               5                   10      


<210>  26
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR2 of the anti-Loricrin antibody

<400>  26

Asp Asp Asn Glu Arg Pro Ser 
1               5           


<210>  27
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR3 of the anti-Loricrin antibody

<400>  27

Gln Ser Tyr Asp Ser Gly Asn Arg Val 
1               5                   


<210>  28
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCFR1 of the anti-Loricrin antibody

<400>  28

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn 
            20                  25                  30  


<210>  29
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCFR2 of the anti-Loricrin antibody

<400>  29

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly 
1               5                   10                  


<210>  30
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCFR3 of the anti-Loricrin antibody

<400>  30

Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu 
1               5                   10                  15      


Leu Ser Arg Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210>  31
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCFR4 of the anti-Loricrin antibody

<400>  31

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  32
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCFR1 of the anti-Loricrin antibody

<400>  32

Asp Ile Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Ser Ile Thr Cys 
            20          


<210>  33
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCFR2 of the anti-Loricrin antibody

<400>  33

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
1               5                   10                  15  


<210>  34
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCFR3 of the anti-Loricrin antibody

<400>  34

Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr 
1               5                   10                  15      


Leu Thr Ile Ser Gly Thr Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys 
            20                  25                  30          


<210>  35
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCFR4 of the anti-Loricrin antibody

<400>  35

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 
1               5                   10          


<210>  36
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH domain of the anti-Loricrin antibody

<400>  36

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn Asp Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Val Ile Ser Pro Asn Ser Gly Lys Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Leu Tyr Pro Asp Ser Ser Ala Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  37
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL domain of the anti-Loricrin antibody

<400>  37

Asp Ile Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Leu Gly Asp Lys Tyr Ala 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Asp Asp Asn Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Glu 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Gly Asn Arg Val 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 
            100                 105             


<210>  38
<211>  222
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fd chain (VH domain and constant domain) of the Fab region of the
       anti-Loricrin antibody

<400>  38

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn Asp Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Val Ile Ser Pro Asn Ser Gly Lys Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Leu Tyr Pro Asp Ser Ser Ala Phe Asp Ile Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 
        115                 120                 125             


Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 
    130                 135                 140                 


Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 
145                 150                 155                 160 


Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 
                165                 170                 175     


Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 
            180                 185                 190         


Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 
        195                 200                 205             


Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 
    210                 215                 220         


<210>  39
<211>  211
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain (VL domain and constant domain) of the Fab region of 
       the anti-Loricrin antibody

<400>  39

Asp Ile Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Leu Gly Asp Lys Tyr Ala 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Asp Asp Asn Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Glu 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Gly Asn Arg Val 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala 
            100                 105                 110         


Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn 
        115                 120                 125             


Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val 
    130                 135                 140                 


Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu 
145                 150                 155                 160 


Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser 
                165                 170                 175     


Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser 
            180                 185                 190         


Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro 
        195                 200                 205             


Thr Glu Ala 
    210     


<210>  40
<211>  2079
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Fd chain of the Fab region and tags of the anti-Loricrin antibody

<400>  40
caggtgcaat tggtgcagag cggtgcggaa gtgaaaaaac cgggtgccag cgtgaaagtt       60

agctgcaaag cgtccggata taccttcaac gactactaca tccattgggt gcgccaggcc      120

ccgggccagg gcctcgagtg gatgggcgtt atctctccga actctggcaa aacgaactac      180

gcgcagaaat ttcagggccg ggtgaccatg acccgtgata ccagcattag caccgcgtat      240

atggaactga gccgtctgcg tagcgaagat acggccgtgt attattgcgc gcgtgacctg      300

tacccggact cttctgcttt cgatatctgg ggccaaggca ccctggtgac tgttagctca      360

gcgtcgacca aaggcccgag cgtgtttccg ctggccccga gcagcaaaag caccagcggc      420

ggcaccgccg cactgggctg cctggtgaaa gattatttcc cggaaccagt gaccgtgagc      480

tggaacagcg gtgccctgac cagcggcgtg catacctttc cggcggtgct gcaaagcagc      540

ggcctgtata gcctgagcag cgttgtgacc gtgccgagca gcagcctggg cacccagacc      600

tatatttgca acgtcaacca taaaccgagc aacaccaaag tcgataaaaa agtcgaaccg      660

aaaagcgaat tcaaggctga aatgcctgtt ctggaaaacc gggctgctca gggcgatatt      720

actacacccg gcggtgctcg ccgtttaacg ggtgatcaga ctgccgctct gcgtgattct      780

cttagcgata aacctgcaaa aaatattatt ttgctgattg gcgatgggat gggggactcg      840

gaaattactg ccgcacgtaa ttatgccgaa ggtgcgggcg gcttttttaa aggtatagat      900

gccttaccgc ttaccgggca atacactcac tatgcgctga atagaaaaac cggcaaaccg      960

gactacgtca ccagctcggc tgcatcagca accgcctggt caaccggtgt caaaacctat     1020

aacggcgcgc tgggcgtcga tattcacgaa aaagatcacc caacgattct ggaaatggca     1080

aaagccgcag gtctggcgac cggtaacgtt tctaccgcag agttgcagga tgccacgccc     1140

gctgcgctgg tggcacatgt gacctcgcgc aaatgctacg gtccgagcgc gaccagtgaa     1200

aaatgtccgg gtaacgctct ggaaaaaggc ggaaaaggat cgattaccga acagctgctt     1260

aacgctcgtg ccgacgttac gcttggcggc ggcgcaaaaa cctttgctga aacggcaacc     1320

gctggtgaat ggcagggaaa aacgctgcgt gaacaggcac aggcgcgtgg ttatcagttg     1380

gtgagcgatg ctgcctcact gaactcggtg acggaagcga atcagcaaaa acccctgctt     1440

ggcctgtttg ctgacggcaa tatgccagtg cgctggctag gaccgaaagc aacgtaccat     1500

ggcaatatcg ataagcccgc agtcacctgt acgccaaatc cgcaacgtaa tgacagtgta     1560

ccaaccctgg cgcagatgac cgacaaagcc attgaattgt tgagtaaaaa tgagaaaggc     1620

tttttcctgc aagttgaagg tgcgtcaatc gataaacagg atcatgctgc gaatccttgt     1680

gggcaaattg gcgagacggt cgatctcgat gaagccgtac aacgggcgct ggagttcgct     1740

aaaaaggagg gtaacacgct ggtcatagtc accgctgatc acgcccacgc cagccagatt     1800

gttgcgccgg ataccaaagc tccgggcctc acccaggcgc taaataccaa agatggcgca     1860

gtgatggtga tgagttacgg gaactccgaa gaggattcac aagaacatac cggcagtcag     1920

ttgcgtattg cggcgtatgg cccgcatgcc gccaatgttg ttggactgac cgaccagacc     1980

gatctcttct acaccatgaa agccgctctg gggctgaaag gcgcgccgga ctataaagat     2040

gacgatgaca aaggcgcgcc gcaccatcat caccatcac                            2079


<210>  41
<211>  633
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  the light chain of the Fab region of the anti-Loricrin antibody

<400>  41
gatatcgaac tgacccagcc gccgagcgtg agcgtgagcc cgggccagac cgcgagcatt       60

acctgtagcg gcgataacct gggtgacaaa tacgctcatt ggtaccagca gaaaccgggc      120

caggcgccgg tgctggtgat ctacgacgac aacgaacgtc cgagcggcat cccggaacgt      180

tttagcggat ccaacagcgg caacaccgcg accctgacca ttagcggcac ccaggcggaa      240

gacgaagcgg attattactg ccagtcttac gactctggta accgtgtgtt tggcggcggc      300

acgaagttaa ccgttcttgg ccagccgaaa gccgccccaa gcgtgaccct gtttccgccg      360

agcagcgaag aactgcaagc caacaaagcc accctggttt gcctgatcag cgatttttat      420

ccgggtgccg tgaccgtggc ctggaaagcc gatagcagcc cggtgaaagc cggcgtggaa      480

accaccaccc cgagcaaaca gagcaacaac aaatatgccg ccagcagcta tctgagcctg      540

accccggaac agtggaaaag ccatcgcagc tatagttgtc aagtgaccca tgaaggcagc      600

accgtggaaa aaaccgtggc cccgaccgag gcc                                   633


<210>  42
<211>  312
<212>  PRT
<213>  Homo sapiens

<400>  42

Met Ser Tyr Gln Lys Lys Gln Pro Thr Pro Gln Pro Pro Val Asp Cys 
1               5                   10                  15      


Val Lys Thr Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly 
            20                  25                  30          


Gly Cys Gly Phe Phe Gly Gly Gly Gly Ser Gly Gly Gly Ser Ser Gly 
        35                  40                  45              


Ser Gly Cys Gly Tyr Ser Gly Gly Gly Gly Tyr Ser Gly Gly Gly Cys 
    50                  55                  60                  


Gly Gly Gly Ser Ser Gly Gly Gly Gly Gly Gly Gly Ile Gly Gly Cys 
65                  70                  75                  80  


Gly Gly Gly Ser Gly Gly Ser Val Lys Tyr Ser Gly Gly Gly Gly Ser 
                85                  90                  95      


Ser Gly Gly Gly Ser Gly Cys Phe Ser Ser Gly Gly Gly Gly Ser Gly 
            100                 105                 110         


Cys Phe Ser Ser Gly Gly Gly Gly Ser Ser Gly Gly Gly Ser Gly Cys 
        115                 120                 125             


Phe Ser Ser Gly Gly Gly Gly Ser Ser Gly Gly Gly Ser Gly Cys Phe 
    130                 135                 140                 


Ser Ser Gly Gly Gly Gly Phe Ser Gly Gln Ala Val Gln Cys Gln Ser 
145                 150                 155                 160 


Tyr Gly Gly Val Ser Ser Gly Gly Ser Ser Gly Gly Gly Ser Gly Cys 
                165                 170                 175     


Phe Ser Ser Gly Gly Gly Gly Gly Ser Val Cys Gly Tyr Ser Gly Gly 
            180                 185                 190         


Gly Ser Gly Cys Gly Gly Gly Ser Ser Gly Gly Ser Gly Ser Gly Tyr 
        195                 200                 205             


Val Ser Ser Gln Gln Val Thr Gln Thr Ser Cys Ala Pro Gln Pro Ser 
    210                 215                 220                 


Tyr Gly Gly Gly Ser Ser Gly Gly Gly Gly Ser Gly Gly Ser Gly Cys 
225                 230                 235                 240 


Phe Ser Ser Gly Gly Gly Gly Gly Ser Ser Gly Cys Gly Gly Gly Ser 
                245                 250                 255     


Ser Gly Ile Gly Ser Gly Cys Ile Ile Ser Gly Gly Gly Ser Val Cys 
            260                 265                 270         


Gly Gly Gly Ser Ser Gly Gly Gly Gly Gly Gly Ser Ser Val Gly Gly 
        275                 280                 285             


Ser Gly Ser Gly Lys Gly Val Pro Ile Cys His Gln Thr Gln Gln Lys 
    290                 295                 300                 


Gln Ala Pro Thr Trp Pro Ser Lys 
305                 310         


<210>  43
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  exemplary epitope tag

<400>  43

Asp Tyr Lys Asp Asp Asp Asp Lys 
1               5               


<210>  44
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  exemplary epitope tag

<400>  44

Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr 
1               5                   10                  


<210>  45
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  exemplary epitope tag

<400>  45

Trp Ser His Pro Gln Phe Glu Lys 
1               5               


<210>  46
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide to which anti-Ambra-1 antibodies were raised

<400>  46

Cys Gly Gly Ser Ser Arg Gly Asp Ala Ala Gly Pro Arg Gly Glu Pro 
1               5                   10                  15      


Arg Asn Arg 
            


<210>  47
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  His6 tag

<400>  47

His His His His His His 
1               5       


<210>  48
<211>  41
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ambra-1 C-terminal sequence used for replacement analysis in 
       epitope mapping

<400>  48

Val Ser Leu Pro Ser Ala Glu Gly Pro Thr Leu His Cys Glu Leu Thr 
1               5                   10                  15      


Asn Asn Asn His Leu Leu Asp Gly Gly Ser Ser Arg Gly Asp Ala Ala 
            20                  25                  30          


Gly Pro Arg Gly Glu Pro Arg Asn Arg 
        35                  40      


<210>  49
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  REPNET epitope of the Anti-Ambra-1 antibodies

<400>  49

Asp Gly Gly Ser Ser Arg Gly Asp Ala Ala Gly Pro Arg Gly Glu Pro 
1               5                   10                  15      


Arg Asn Arg 
            


<210>  50
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LIN epitope of the Anti-Ambra-1 antibodies

<400>  50

His Leu Leu Asp Gly Gly Ser Ser Arg 
1               5                   


<210>  51
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LOOP epitope of the Anti-Ambra-1 antibodies

<400>  51

Asn His Leu Leu Asp Gly Gly Ser Ser Arg 
1               5                   10  


<210>  52
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  core epitope of the Anti-Ambra-1 antibodies

<400>  52

Glu Pro Arg Asn 
1               


<210>  53
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  core epitope of the Anti-Ambra-1 antibodies

<400>  53

Glu Pro Arg 
1           


<210>  54
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  epitope of the Anti- Loricrin antibodies

<400>  54

Ser Tyr Gln Lys Lys Gln Pro Thr Pro Gly Pro Pro Val Asp Cys Val 
1               5                   10                  15      


Lys Thr Ser 
            


<210>  55
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  epitope of the Anti- Loricrin antibodies

<400>  55

Gly Gly Gly Gly Ile Gly Gly Pro Gly Gly Gly Ser Gly Gly Ser Val 
1               5                   10                  15      


Lys Tyr Ser 
            


<210>  56
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  epitope of the Anti- Loricrin antibodies

<400>  56

Gly Ser Ser Gly Gly Gly Ser Gly Cys Phe Ser Ser Gly Gly Gly 
1               5                   10                  15  


<210>  57
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  epitope of the Anti- Loricrin antibodies

<400>  57

Gly Ile Gly Ser Gly Cys Ile Ile Ser Gly Gly Gly Ser Val Cys Gly 
1               5                   10                  15      


Gly Gly Ser 
            


<210>  58
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  epitope of the Anti- Loricrin antibodies

<400>  58

Gly Ser Ser Gly Gly Gly Gly Gly Gly Ser Ser Val Gly Gly Ser Gly 
1               5                   10                  15      


Ser Gly Lys 
            


<210>  59
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  epitope of the Anti- Loricrin antibodies

<400>  59

Gly Val Cys Ile Cys His Gln Thr Gln Gln Lys 
1               5                   10      


<210>  60
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  core epitope of the Anti- Loricrin antibodies

<400>  60

Val Lys Tyr Ser 
1               


<210>  61
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  core epitope of the Anti- Loricrin antibodies

<400>  61

Cys Phe Ser 
1           


